市場調査レポート
商品コード
1439264
心臓補助装置 - 世界市場の考察、競合情勢、市場予測(2030年)Cardiac Assist Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
心臓補助装置 - 世界市場の考察、競合情勢、市場予測(2030年) |
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界の心臓補助装置の市場規模は、2023年に28億9,000万米ドル、2030年までに62億3,000万米ドルに達し、2024年~2030年の予測期間にCAGRで13.70%の成長が見込まれます。心臓補助装置の需要は、冠動脈疾患の有病率の上昇、新治療法の成長、医療装置の手頃な価格、新興国における心臓補助装置の普及と受け入れの増加、医療装置の革新と進歩が促進要因となっています。
心臓補助装置の市場力学
心臓移植は、世界中の末期心不全患者にとって最大の治療オプションであると広く認識されています。移植に利用できる臓器が不足しているため、移植を受けられる患者の割合は限られています。最新の統計によると、心臓移植を待つ患者の数はわずか5年で2倍超に増えています。しかし、ドナーの不足、待ち時間の長さ、不安定な患者の増加が、心臓補助装置の開発を後押ししています。
心臓補助装置(CAD)は機械式ポンプの一種であり、心臓とともに作動してポンプの効果を高め、体全体の最適な血流を維持します。末期心不全の治療には、個人のニーズに応じて心臓補助装置が使用されます。心臓ドナーが不足しているため、一時的な心臓補助装置が個人の長期的な補助に利用されています。
American Heart Associationのレポート(2020)によると、心不全の有病率は高齢化に伴い、時間とともに増加し続けています。高齢患者の増加により、医療の提供が変化し、心臓補助装置の需要が増加すると予測されています。近年の調査、Global Population Aging 2020 Report(国連、2020)によると、老年人口は憂慮すべきペースで増加傾向にあります。2020年に、世界には65歳以上の高齢者が約7億2,700万人います。2050年までに、このような患者の数は倍増し、15億人に達すると予測されています。高齢者は心血管障害を引き起こしやすいため、心臓補助装置の需要が高まり、心臓補助装置市場が活性化します。
さらに、企業は必要不可欠な医療装置製品の製造を増やしています。例えば、2022年8月、FDAはAbiomedのImpella ECP拡張型経皮的心臓ポンプに画期的医療機器指定を与えました。この指定は、FDAがImpella ECPの設計イテレーション、臨床試験プロトコル、市販前承認(PMA)申請などの規制審査プロセスを優先することを意味します。
したがって、このような取り組みは市場や患者の治療に役立ち、また心臓補助装置市場の成長を促進すると予測されています。
しかし、高い治療費と植込み型装置の安全性に関する制限が、心臓補助装置市場の成長に対する一定の抑制要因になる可能性があります。
心臓補助装置市場のセグメント分析
心臓補助装置市場の製品セグメントでは、補助人工心臓が予測期間に大きなシェアを占めると予測されています。これは主に、技術の進歩とLVADに関連する利点や用途、臓器提供者の不足、世界の心不全有病率の増加に起因しています。
LVADは正常な血流を回復させることで重症心不全患者の治療を目的としています。心不全患者へのLVADの移植は救命につながり、臓器移植までの時間を稼ぐことができます。
LVADは信頼性が高く、安全システムが組み込まれています。
LVADの植込み後、患者は健康状態の改善を見せ、運動やその他の日常活動に復帰/再開することができます。
LVADは重症心不全患者に中長期的な治療ソリューションを提供します。さらに、政府機関からの援助や有利な償還シナリオは、いくつかの国で心臓補助装置市場の将来性を高めると予測されています。
したがって、上記のすべての要因がこのセグメントの成長を促進すると予測されます。
当レポートでは、世界の心臓補助装置市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。
Cardiac Assist Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Artificial Heart, and Intra-Aortic Balloon Pump), Type (Transcutaneous and Implantable), Therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, and Bridge-To-Candidacy (BTC Therapy), End-User (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to growth in new therapies and increasing prevalence of coronary diseases.
The global cardiac assist devices market was valued at USD 2.89 billion in 2023, growing at a CAGR of 13.70% during the forecast period from 2024 to 2030, to reach USD 6.23 billion by 2030. The demand for cardiac assistance devices is motivated by a rise in the prevalence of coronary diseases, growth in new therapies, the affordability of medical devices, increasing penetration and acceptance of cardiac assistance devices in emerging countries, and innovation and advancement of medical devices.
Cardiac Assist Devices Market Dynamics:
Heart transplantation is widely regarded as the greatest therapeutic option for individuals with end-stage heart failure across the world. Only a limited percentage of patients get transplants due to the scarcity of organs available for transplantation. According to the most recent statistics, the number of patients waiting for a heart transplant has more than doubled in only five years. However, the scarcity of donors, long waiting times, and an increasing number of unstable patients have favored the development of cardiac assist.
Cardiac Assist Devices (CAD) are a type of mechanical pump that operate together with the heart to increase the effectiveness of pumping and maintain optimal blood flow across the body. To treat end-stage heart failure, cardiac aid systems are used that are determined by the individual's needs. As a result of the scarcity of cardiac donors, temporary cardiac assist devices are utilized to provide long-term assistance for individuals.
According to a report from the American Heart Association, 2020, the prevalence of heart failure continues to increase over time, with the aging of the population. It is predicted that the rising number of elderly patients would transform healthcare delivery and create a larger demand for cardiac assist devices. As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure for such patients is expected to double and reach 1.5 billion by 2050. Since the aging population is more prone to cardiovascular disorders, therefore it will give rise to more demand for cardiac assist devices, which will boost the cardiac assist devices market.
Moreover, companies are increasing their manufacturing of essential medical device products. For instance, in August 2022, the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols, and pre-market approval (PMA) application.
Therefore, such initiatives are expected to help the market and the patients in their treatment which will drive the cardiac assist devices market growth also.
However, high treatment costs and limitations regarding the safety of implantable devices may prove to be certain restraints to the Cardiac Assist Devices market growth.
Cardiac Assist Devices Market Segment Analysis:
Cardiac Assist Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Artificial Heart, and Intra-Aortic Balloon Pump), Type (Transcutaneous and Implantable), Therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, and Bridge-To-Candidacy (BTC Therapy), End-User (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the cardiac assist devices market product segment under the ventricular assist devices category, left ventricular assist devices are expected to hold a significant share during the forecast period. It is primarily attributed to the advantages and applications associated with LVAD coupled with increasing technological advancements, the scarcity of organ donors, and the increasing prevalence of heart failure globally.
LVAD is intended for the treatment of patients with severe heart failure by restoring normal blood flow. The implantation of LVAD in heart failure patients can be life-saving and buys more time for them till organ transplantation.
LVADs are highly reliable and come with built-in safety systems.
Post implantation of LVAD, patients witness improvement in their health and can return/resume their daily activities including driving, and others.
LVADs offer intermediate to long-term treatment solutions for severe heart failure patients. Additionally, assistance from government bodies, and favorable reimbursement scenarios, are expected to enhance the cardiac assist devices market potential in several countries.
Hence, all the above-mentioned factors are expected to drive the segment growth.
North America is expected to dominate the Overall Cardiac Assist Devices Market:
Among all the regions, North America is expected to account for the largest share of the cardiac assist devices market. The growing prevalence of cardiovascular diseases, access to better healthcare infrastructure, and growing awareness regarding cardiac diseases coupled with the presence of major cardiac assist devices market players in the region are predicted to be the major influencing factors in driving the overall growth of the cardiac assist devices market over the forecast period.
The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020. Also, the same source stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.
As per the facts provided by the CDC 2020, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States where about 655,000 Americans die from heart disease each year.
In addition, the well-established healthcare infrastructure in the country with supportive reimbursement programs covering the costs for the implantable devices as well as the procedure further encourages people to opt for such devices.
Thereby, considering the presence of a large patient pool in the US coupled with new product launches, the market for cardiac assist devices looks promising in the United States.
Cardiac Assist Devices Market Key Players:
Some of the key market players operating in the cardiac assist devices market include Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, Inc., NovaPump GmbH, Getinge AB, Balton Ltd., Meril Life Sciences Pvt. Ltd., Thoratec Corporation, CardiacAssist, Inc., Berlin Heart GmbH, and others.
Recent Developmental Activities in the Cardiac Assist Devices Market:
In December 2020, Abbott received FDA approval for the updated labeling for the HeartMate 3 Heart Pump to be used in pediatric patients with advanced refractory left ventricular heart failure.
In March 2020, the US-based healthcare giant, SynCardia Systems LLC, got approval from the US FDA for a 50CC temporary total artificial heart system as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
Key Takeaways from the Cardiac Assist Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global cardiac assist devices market.
Various opportunities are available for the other competitor in the cardiac assist devices market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for cardiac assist devices market growth in the coming future?
Target Audience who can be benefited from this Cardiac Assist Devices Market Report Study
Cardiac Assist Devices providers
Research organizations and consulting companies
Cardiac Assist Devices related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in cardiac assist devices
Various End-users want to know more about the cardiac assist devices market and the latest technological developments in the cardiac assist devices market.
Frequently Asked Questions for Cardiac Assist Devices Market:
Cardiac Assist Devices (CAD) are a type of mechanical pump that operate together with the heart to increase the effectiveness of pumping and maintain optimal blood flow across the body. To treat end-stage heart failure, cardiac aid systems are used that are determined by the individual's needs. As a result of the scarcity of cardiac donors, temporary cardiac assist devices are utilized to provide long-term assistance for individuals.
The global cardiac assist devices market was valued at USD 2.89 billion in 2023, growing at a CAGR of 13.70% during the forecast period from 2024 to 2030, to reach USD 6.23 billion by 2030.
The major drivers driving the demand for cardiac assist devices are a rise in the prevalence of coronary diseases, growth in new therapies, the affordability of medical devices, increasing penetration and acceptance of cardiac assistance devices in emerging countries, and innovation and advancement of medical devices.
Some of the key market players operating in the cardiac assist devices market include Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, Inc., NovaPump GmbH, Getinge AB, Balton Ltd., Meril Life Sciences Pvt. Ltd., Thoratec Corporation, CardiacAssist, Inc., Berlin Heart GmbH, and others.
North America is expected to dominate the overall cardiac assist devices market during the forecast period, 2024 to 2030. This domination is due to the growing prevalence of cardiovascular diseases, access to better healthcare infrastructure, and growing awareness regarding cardiac diseases coupled with the presence of major cardiac assist devices market players in the region.